Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Others ); Indication (Cardiovascular Diseases, Hypertension, Chronic Kidney Diseases, Diabetes, Scleroderma, Migraines); Distribution Channel (Online Pharmacies, Retail and Hospital Pharmacies), and Geography

Report Code: TIPRE00020853 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Angiotensin converting enzyme inhibitors (ACE inhibitors) are used as medicines to inhibit the enzyme ACE activity. It decreases angiotensin II production that results in the enlargement of blood vessels and blood pressure is reduced. This further lower blood pressure and makes it easier for the heart to pump blood and reduce heart failure chances. In addition, ACE inhibitors help in slowing down the progression of kidney disease due to high blood pressure or diabetes.

MARKET DYNAMICS

The angiotensin converting enzyme (ACE) inhibitors market growth is estimated to grow due to the increasing incidences of cardiovascular and kidney diseases, hypertension and other such chronic conditions. The market is also expected to due to growing biopharmaceutical product development and production. The emerging markets such as Asia Pacific, Middle East and Africa, and South and Central America are likely to serve growth opportunities for the market's growth.

MARKET SCOPE

The "Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of angiotensin converting enzyme (ACE) inhibitors market with detailed market segmentation by product, indication, and distribution channel. The angiotensin converting enzyme (ACE) inhibitors market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in angiotensin converting enzyme (ACE) inhibitors market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The angiotensin converting enzyme (ACE) inhibitors market is segmented on the basis of enzyme product, indication, and distribution channel. Based on product, the market is classified as benazepril, captopril, enalapril, fosinopril, lisinopril, and others. On the basis of indication, the market is segmented as cardiovascular diseases, hypertension, chronic kidney diseases, diabetes, scleroderma, and migraines. And based on the distribution channel, the market is segmented as online pharmacies, retail and hospital pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the angiotensin converting enzyme (ACE) inhibitors market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America (SCAM). The angiotensin converting enzyme (ACE) inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting angiotensin converting enzyme (ACE) inhibitors market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the angiotensin converting enzyme (ACE) inhibitors market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the angiotensin converting enzyme (ACE) inhibitors market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angiotensin converting enzyme (ACE) inhibitors market are anticipated to have lucrative growth opportunities in the future with the rising demand for angiotensin converting enzyme (ACE) inhibitors market in the global market. Below mentioned is the list of few companies engaged in the angiotensin converting enzyme (ACE) inhibitors market.

The report also includes the profiles of key players in angiotensin converting enzyme (ACE) inhibitors market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Novartis AG
  •   Pfizer, Inc
  •   Merck & Co., Inc.
  •   Bristol Myers Squibb
  •   Astra and Zeneca
  •   UCB (Schwarz Pharma Inc.)
  •   Solvay Pharmaceuticals B.V.
  •   Abbott
  •   Endo International (Par Pharmaceutical, Inc.)
  •   Sanofi

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors Market - By Product
1.3.2 Angiotensin Converting Enzyme (ACE) Inhibitors Market - By Indication
1.3.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market - By Distribution Channel
1.3.4 Angiotensin Converting Enzyme (ACE) Inhibitors Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS - GLOBAL MARKET OVERVIEW
6.2. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. BENAZEPRIL
7.3.1. Overview
7.3.2. Benazepril Market Forecast and Analysis
7.4. CAPTOPRIL
7.4.1. Overview
7.4.2. Captopril Market Forecast and Analysis
7.5. ENALAPRIL
7.5.1. Overview
7.5.2. Enalapril Market Forecast and Analysis
7.6. FOSINOPRIL
7.6.1. Overview
7.6.2. Fosinopril Market Forecast and Analysis
7.7. LISINOPRIL
7.7.1. Overview
7.7.2. Lisinopril Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. CARDIOVASCULAR DISEASES
8.3.1. Overview
8.3.2. Cardiovascular Diseases Market Forecast and Analysis
8.4. HYPERTENSION
8.4.1. Overview
8.4.2. Hypertension Market Forecast and Analysis
8.5. CHRONIC KIDNEY DISEASES
8.5.1. Overview
8.5.2. Chronic Kidney Diseases Market Forecast and Analysis
8.6. DIABETES
8.6.1. Overview
8.6.2. Diabetes Market Forecast and Analysis
8.7. SCLERODERMA
8.7.1. Overview
8.7.2. Scleroderma Market Forecast and Analysis
8.8. MIGRAINES
8.8.1. Overview
8.8.2. Migraines Market Forecast and Analysis
9. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. ONLINE PHARMACIES
9.3.1. Overview
9.3.2. Online Pharmacies Market Forecast and Analysis
9.4. RETAIL AND HOSPITAL PHARMACIES
9.4.1. Overview
9.4.2. Retail and Hospital Pharmacies Market Forecast and Analysis
10. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
10.1.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis
10.1.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Product
10.1.4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Indication
10.1.5 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Countries
10.1.6.1 United States Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.1.6.1.1 United States Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.1.6.1.2 United States Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.1.6.1.3 United States Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.1.6.2 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.1.6.2.1 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.1.6.2.2 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.1.6.2.3 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.1.6.3 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.1.6.3.1 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.1.6.3.2 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.1.6.3.3 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
10.2.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis
10.2.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Product
10.2.4 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Indication
10.2.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.1.1 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.1.2 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.1.3 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2.6.2 France Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.2.1 France Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.2.2 France Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.2.3 France Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2.6.3 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.3.1 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.3.2 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.3.3 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2.6.4 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.4.1 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.4.2 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.4.3 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2.6.5 United Kingdom Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.5.1 United Kingdom Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.5.2 United Kingdom Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.5.3 United Kingdom Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.2.6.6 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.2.6.6.1 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.2.6.6.2 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.2.6.6.3 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
10.3.2 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis
10.3.3 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Product
10.3.4 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.1.1 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.1.2 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.1.3 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3.6.2 China Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.2.1 China Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.2.2 China Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.2.3 China Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3.6.3 India Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.3.1 India Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.3.2 India Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.3.3 India Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3.6.4 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.4.1 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.4.2 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.4.3 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3.6.5 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.5.1 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.5.2 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.5.3 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.3.6.6.1 Rest of Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.3.6.6.2 Rest of Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.3.6.6.3 Rest of Asia-Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
10.4.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis
10.4.3 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Product
10.4.4 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.4.6.1.1 South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.4.6.1.2 South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.4.6.1.3 South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.4.6.2 Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.4.6.2.1 Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.4.6.2.2 Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.4.6.2.3 Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.4.6.3 U.A.E Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.4.6.3.1 U.A.E Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.4.6.3.2 U.A.E Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.4.6.3.3 U.A.E Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.4.6.4.1 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.4.6.4.2 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.4.6.4.3 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
10.5.2 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis
10.5.3 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Product
10.5.4 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.5.6.1.1 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.5.6.1.2 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.5.6.1.3 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.5.6.2 Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.5.6.2.1 Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.5.6.2.2 Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.5.6.2.3 Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
10.5.6.3 Rest of South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market
10.5.6.3.1 Rest of South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market by Product
10.5.6.3.2 Rest of South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market by Indication
10.5.6.3.3 Rest of South and Central America Angiotensin Converting Enzyme (ACE) Inhibitors Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS MARKET, KEY COMPANY PROFILES
13.1. NOVARTIS AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. PFIZER, INC
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. MERCK AND CO., INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. BRISTOL MYERS SQUIBB
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ASTRA AND ZENECA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. UCB (SCHWARZ PHARMA INC.)
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. SOLVAY PHARMACEUTICALS B.V.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ABBOTT
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ENDO INTERNATIONAL (PAR PHARMACEUTICAL, INC.)
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. SANOFI
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Pfizer, Inc
3. Merck & Co., Inc.
4. Bristol Myers Squibb
5. Astra and Zeneca
6. UCB (Schwarz Pharma Inc.)
7. Solvay Pharmaceuticals B.V.
8. Abbott
9. Endo International (Par Pharmaceutical, Inc.)
10. Sanofi
11. Johnson & Johnson Services, Inc.
12. Perrigo Company plc
13. United Therapeutics Corporation
14. Daiichi Sankyo Company, Ltd
15. Bayer AG
TIPRE00020853
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking